Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel Free XRTX Stock Alerts

XORTX Therapeutics (XRTX) Competitors

XORTX Therapeutics logo
$2.25 +0.05 (+2.27%)
As of 10:27 AM Eastern
Compare

XRTX vs. NAII, COSM, SCNX, TRAW, and BLRX

Should you buy XORTX Therapeutics stock or one of its competitors? MarketBeat compares XORTX Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with XORTX Therapeutics include Natural Alternatives International (NAII), Cosmos Health (COSM), Scienture (SCNX), Traws Pharma (TRAW), and BioLineRx (BLRX). These companies are all part of the "med - drugs" industry.

How does XORTX Therapeutics compare to Natural Alternatives International?

Natural Alternatives International (NASDAQ:NAII) and XORTX Therapeutics (NASDAQ:XRTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

32.4% of Natural Alternatives International shares are held by institutional investors. Comparatively, 0.2% of XORTX Therapeutics shares are held by institutional investors. 20.8% of Natural Alternatives International shares are held by insiders. Comparatively, 6.9% of XORTX Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Natural Alternatives International has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, XORTX Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

XORTX Therapeutics has a net margin of 0.00% compared to Natural Alternatives International's net margin of -10.13%. Natural Alternatives International's return on equity of -12.21% beat XORTX Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Natural Alternatives International-10.13% -12.21% -5.30%
XORTX Therapeutics N/A -150.01%-106.53%

In the previous week, Natural Alternatives International had 3 more articles in the media than XORTX Therapeutics. MarketBeat recorded 4 mentions for Natural Alternatives International and 1 mentions for XORTX Therapeutics. XORTX Therapeutics' average media sentiment score of 1.31 beat Natural Alternatives International's score of 0.58 indicating that XORTX Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Natural Alternatives International Positive
XORTX Therapeutics Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Natural Alternatives International
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
XORTX Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

XORTX Therapeutics has lower revenue, but higher earnings than Natural Alternatives International. Natural Alternatives International is trading at a lower price-to-earnings ratio than XORTX Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Natural Alternatives International$129.86M0.12-$13.57M-$2.39N/A
XORTX TherapeuticsN/AN/A-$2.66M-$2.63N/A

Summary

Natural Alternatives International beats XORTX Therapeutics on 7 of the 12 factors compared between the two stocks.

How does XORTX Therapeutics compare to Cosmos Health?

XORTX Therapeutics (NASDAQ:XRTX) and Cosmos Health (NASDAQ:COSM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XORTX Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Cosmos Health
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

XORTX Therapeutics has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Cosmos Health has a beta of 4.79, meaning that its share price is 379% more volatile than the broader market.

XORTX Therapeutics has a net margin of 0.00% compared to Cosmos Health's net margin of -30.41%. Cosmos Health's return on equity of -52.85% beat XORTX Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
XORTX TherapeuticsN/A -150.01% -106.53%
Cosmos Health -30.41%-52.85%-17.87%

In the previous week, Cosmos Health had 7 more articles in the media than XORTX Therapeutics. MarketBeat recorded 8 mentions for Cosmos Health and 1 mentions for XORTX Therapeutics. XORTX Therapeutics' average media sentiment score of 1.31 beat Cosmos Health's score of 0.35 indicating that XORTX Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
XORTX Therapeutics Positive
Cosmos Health Neutral

XORTX Therapeutics has higher earnings, but lower revenue than Cosmos Health. XORTX Therapeutics is trading at a lower price-to-earnings ratio than Cosmos Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XORTX TherapeuticsN/AN/A-$2.66M-$2.63N/A
Cosmos Health$65.27M0.23-$19.15M-$0.64N/A

0.2% of XORTX Therapeutics shares are owned by institutional investors. Comparatively, 12.6% of Cosmos Health shares are owned by institutional investors. 6.9% of XORTX Therapeutics shares are owned by insiders. Comparatively, 25.1% of Cosmos Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Cosmos Health beats XORTX Therapeutics on 9 of the 12 factors compared between the two stocks.

How does XORTX Therapeutics compare to Scienture?

XORTX Therapeutics (NASDAQ:XRTX) and Scienture (NASDAQ:SCNX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

Scienture's return on equity of -56.28% beat XORTX Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
XORTX TherapeuticsN/A -150.01% -106.53%
Scienture N/A -56.28%-44.76%

In the previous week, Scienture had 2 more articles in the media than XORTX Therapeutics. MarketBeat recorded 3 mentions for Scienture and 1 mentions for XORTX Therapeutics. XORTX Therapeutics' average media sentiment score of 1.31 beat Scienture's score of 0.69 indicating that XORTX Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
XORTX Therapeutics Positive
Scienture Positive

XORTX Therapeutics has higher earnings, but lower revenue than Scienture. XORTX Therapeutics is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XORTX TherapeuticsN/AN/A-$2.66M-$2.63N/A
Scienture$430K35.91-$41.51M-$2.51N/A

XORTX Therapeutics has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Scienture has a beta of 3.29, meaning that its stock price is 229% more volatile than the broader market.

0.2% of XORTX Therapeutics shares are owned by institutional investors. Comparatively, 5.7% of Scienture shares are owned by institutional investors. 6.9% of XORTX Therapeutics shares are owned by company insiders. Comparatively, 21.4% of Scienture shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Scienture has a consensus target price of $1.50, suggesting a potential upside of 294.74%. Given Scienture's stronger consensus rating and higher possible upside, analysts clearly believe Scienture is more favorable than XORTX Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XORTX Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Scienture
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Scienture beats XORTX Therapeutics on 12 of the 14 factors compared between the two stocks.

How does XORTX Therapeutics compare to Traws Pharma?

Traws Pharma (NASDAQ:TRAW) and XORTX Therapeutics (NASDAQ:XRTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

Traws Pharma has higher revenue and earnings than XORTX Therapeutics. Traws Pharma is trading at a lower price-to-earnings ratio than XORTX Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Traws Pharma$2.79M5.32$9.17M-$1.69N/A
XORTX TherapeuticsN/AN/A-$2.66M-$2.63N/A

Traws Pharma presently has a consensus price target of $8.00, suggesting a potential upside of 447.57%. Given Traws Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Traws Pharma is more favorable than XORTX Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Traws Pharma
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50
XORTX Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

XORTX Therapeutics' return on equity of -150.01% beat Traws Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Traws PharmaN/A -913.18% -133.88%
XORTX Therapeutics N/A -150.01%-106.53%

In the previous week, Traws Pharma had 2 more articles in the media than XORTX Therapeutics. MarketBeat recorded 3 mentions for Traws Pharma and 1 mentions for XORTX Therapeutics. XORTX Therapeutics' average media sentiment score of 1.31 beat Traws Pharma's score of 0.60 indicating that XORTX Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Traws Pharma Positive
XORTX Therapeutics Positive

Traws Pharma has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market. Comparatively, XORTX Therapeutics has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

8.0% of Traws Pharma shares are held by institutional investors. Comparatively, 0.2% of XORTX Therapeutics shares are held by institutional investors. 14.0% of Traws Pharma shares are held by company insiders. Comparatively, 6.9% of XORTX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Traws Pharma beats XORTX Therapeutics on 11 of the 15 factors compared between the two stocks.

How does XORTX Therapeutics compare to BioLineRx?

XORTX Therapeutics (NASDAQ:XRTX) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XORTX Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
BioLineRx
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

XORTX Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, BioLineRx has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market.

0.2% of XORTX Therapeutics shares are held by institutional investors. Comparatively, 1.6% of BioLineRx shares are held by institutional investors. 6.9% of XORTX Therapeutics shares are held by company insiders. Comparatively, 1.1% of BioLineRx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

BioLineRx has higher revenue and earnings than XORTX Therapeutics. BioLineRx is trading at a lower price-to-earnings ratio than XORTX Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XORTX TherapeuticsN/AN/A-$2.66M-$2.63N/A
BioLineRx$1.40M10.53-$1.17M-$1.92N/A

XORTX Therapeutics has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. BioLineRx's return on equity of -37.73% beat XORTX Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
XORTX TherapeuticsN/A -150.01% -106.53%
BioLineRx -563.70%-37.73%-19.42%

In the previous week, BioLineRx had 8 more articles in the media than XORTX Therapeutics. MarketBeat recorded 9 mentions for BioLineRx and 1 mentions for XORTX Therapeutics. XORTX Therapeutics' average media sentiment score of 1.31 beat BioLineRx's score of 0.32 indicating that XORTX Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
XORTX Therapeutics Positive
BioLineRx Neutral

Summary

BioLineRx beats XORTX Therapeutics on 10 of the 14 factors compared between the two stocks.

Get XORTX Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for XRTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

XRTX vs. The Competition

Export
MetricXORTX TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.90M$2.90B$6.25B$12.49B
Dividend YieldN/A1.79%2.69%5.30%
P/E Ratio-0.8617.6421.0724.34
Price / SalesN/A484.07556.32125.86
Price / CashN/A56.3842.3157.88
Price / Book1.503.849.786.76
Net Income-$2.66M$75.85M$3.56B$337.09M
7 Day Performance-6.25%-1.74%-0.18%1.50%
1 Month Performance-19.06%22.80%4.95%6.18%
1 Year Performance-52.12%21.59%28.44%35.62%

XORTX Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
XRTX
XORTX Therapeutics
0.8728 of 5 stars		$2.25
+2.3%		N/A-52.6%$3.90MN/AN/AN/A
NAII
Natural Alternatives International
1.702 of 5 stars		$2.64
+0.4%		N/A-23.8%$16.50M$129.86MN/A290
COSM
Cosmos Health
0.9627 of 5 stars		$0.26
-2.2%		N/A-43.1%$15.90M$65.27MN/A100
SCNX
Scienture
3.0565 of 5 stars		$0.42
+7.1%		$1.50
+258.1%		-55.6%$15.89M$430KN/AN/A
TRAW
Traws Pharma
3.1688 of 5 stars		$1.52
-0.7%		$8.00
+426.3%		+0.0%$15.54M$2.79MN/A17

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:XRTX) was last updated on 6/3/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel